PDS Biotechnology (PDSB) Other Non-Current Liabilities (2014 - 2018)
PDS Biotechnology's (PDSB) quarterly Other Non-Current Liabilities came in at $291225.0 in Q4 2018, down 92.18% on a QoQ basis from $3.7 million in Q3 2015.
PDS Biotechnology (PDSB) Other Non-Current Liabilities (2014 - 2018) Analysis & Trends
PDS Biotechnology (PDSB) has 3 years of Other Non-Current Liabilities data on file, last reported at $291225.0 in Q4 2018.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $291225.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $291225.0 (changed N/A YoY) and the FY2018 annual result came in at $291225.0, changed N/A from the prior year.
- Other Non-Current Liabilities retreated to $291225.0 in Q4 2018, from $3.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.7 million in Q3 2015 to a low of $291225.0 in Q4 2018.
- A 3-year average of $1.9 million and a median of $1.7 million in 2014 frame the typical range for Other Non-Current Liabilities.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 291,225.00 |
| Sep 30, 2015 | 3.73 Mn |
| Dec 31, 2014 | 1.67 Mn |